廣告
香港股市 已收市
  • 恒指

    16,251.84
    +2.87 (+0.02%)
     
  • 國指

    5,749.69
    +5.91 (+0.10%)
     
  • 上證綜指

    3,071.38
    +64.31 (+2.14%)
     
  • 道指

    37,681.47
    -117.50 (-0.31%)
     
  • 標普 500

    5,031.52
    -19.89 (-0.39%)
     
  • 納指

    15,766.00
    -99.25 (-0.63%)
     
  • Vix指數

    18.26
    -0.14 (-0.76%)
     
  • 富時100

    7,859.35
    +38.99 (+0.50%)
     
  • 紐約期油

    84.20
    -1.16 (-1.36%)
     
  • 金價

    2,399.00
    -8.80 (-0.37%)
     
  • 美元

    7.8310
    -0.0002 (-0.00%)
     
  • 人民幣

    0.9239
    +0.0004 (+0.04%)
     
  • 日圓

    0.0504
    +0.0000 (+0.04%)
     
  • 歐元

    8.3345
    +0.0210 (+0.25%)
     
  • Bitcoin

    60,307.30
    -1,658.42 (-2.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines

  • The U.S. government will provide up to $75 million to expand U.K.-listed Croda International Plc's (OTC: COIHF) U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.

  • Croda will also invest up to $58 million.

  • The investment will be used to establish a new lipid facility in Lamar, Pennsylvania. Construction is expected to start later this year, with the new capacity anticipated in 2025.

  • The investment supports the expansion of Croda's portfolio, by creating a third manufacturing site for lipid systems, alongside Croda's existing Alabaster, Alabama, U.S. (Avanti) and Leek, U.K. capabilities.

  • The cooperative agreement is a joint award from the Biomedical Advanced Research and Development Authority (BARDA), and an arm of the U.S. Department of defense will join forces for preparedness for future health emergencies.

  • Financial Times writes that Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines were the first approved jabs to be made with mRNA technology.

  • The vaccines rely on bubbles of fat known as lipid nanoparticles to deliver genetic codes that teach the immune system to recognize the virus.

  • Lipid systems offer significant potential as the delivery system for many nucleic acid applications, including novel mRNA-based therapeutics, such as flu vaccines and cancer treatments.

  • Given the current clinical development pipeline's scale, the lipid systems market is expected to grow significantly over the next ten years.

  • Image by Spencer Davis from Pixabay

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.